BioCentury | Oct 19, 2018
Clinical News

Eisai, Purdue insomnia candidate meets in second Phase III

...March, the partners said lemborexant met the primary and secondary endpoints vs. both placebo and zolpidem...
BioCentury | Oct 17, 2018
Clinical News

Eisai, Purdue insomnia candidate meets in second Phase III

...March, the partners said lemborexant met the primary and secondary endpoints vs. both placebo and zolpidem...
BioCentury | Jun 15, 2018
Clinical News

Eisai, Purdue's insomnia candidate does not impair driving in Phase I

...met the primary endpoint of improving Latency to Persistent Sleep (LPS) vs. both placebo and zolpidem...
BioCentury | Jun 15, 2018
Clinical News

Eisai, Purdue's insomnia candidate improves postural stability in Phase I

...of improving postural stability as measured by mean changes from baseline in body sway vs. zolpidem...
...older to receive a single dose of placebo, 5 or 10 mg oral lemborexant or zolpidem...
...5.8 units for low-dose lemborexant and 8.1 units for high-dose lemborexant vs. 20.4 units for zolpidem...
BioCentury | Mar 16, 2018
Clinical News

Eisai, Purdue's lemborexant meets in Phase III for insomnia

...met the primary endpoint of improving Latency to Persistent Sleep (LPS) vs. both placebo and zolpidem...
...endpoints of improving sleep efficiency and Wake After Sleep Onset (WASO) vs. both placebo and zolpidem...
BioCentury | May 19, 2017
Clinical News

Lorediplon meets in Phase II insomnia trial

...met the secondary endpoint of improving WASO in the second half of the night vs. zolpidem...
BioCentury | Oct 20, 2016
Distillery Therapeutics

Neurology

...antagonist Fycompa perampanel for epilepsy and seizures. Sanofi markets the GABA A receptor agonist Ambien zolpidem...
...University , Binghamton N.Y. email: dlinden1@binghamton.edu CONTACT: Christopher Bishop, same affiliation as above email: cbishop@binghamton.edu Steven Hochhauser Ambien Fycompa Onfi Binghamton...
BioCentury | Sep 12, 2016
Clinical News

Lorediplon: Completed Phase IIa enrollment

...double-blind, placebo-controlled, crossover, international Phase IIa trial comparing 5 and 10 mg oral lorediplon vs. zolpidem...
BioCentury | Jul 27, 2015
Clinical News

Lorediplon: Phase IIa started

...placebo-controlled, crossover, international Phase IIa trial to compare 5 and 10 mg oral Lorediplon vs. zolpidem...
BioCentury | Jan 26, 2015
Company News

Sellas, Catalent Pharma deal

...Catalent and Sellas partnered to reprofile insomnia drug zolpidem to treat Parkinson’s disease (PD) and progressive...
...Catalent will develop the formulation and manufacture and distribute the product. Sellas holds patents covering zolpidem...
Items per page:
1 - 10 of 211